Literature DB >> 32324210

Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib.

Andrea Sartore-Bianchi1,2, Sara Lonardi3, Massimo Aglietta4,5, Cosimo Martino4, Fortunato Ciardiello6, Silvia Marsoni7, Salvatore Siena1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32324210      PMCID： PMC7180725          DOI： 10.1001/jamaoncol.2020.0571

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  5 in total

1.  Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer.

Authors:  Giulia Siravegna; Andrea Sartore-Bianchi; Rebecca J Nagy; Kanwal Raghav; Justin I Odegaard; Richard B Lanman; Livio Trusolino; Silvia Marsoni; Salvatore Siena; Alberto Bardelli
Journal:  Clin Cancer Res       Date:  2019-02-26       Impact factor: 12.531

2.  Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Authors:  Andrea Sartore-Bianchi; Livio Trusolino; Cosimo Martino; Katia Bencardino; Sara Lonardi; Francesca Bergamo; Vittorina Zagonel; Francesco Leone; Ilaria Depetris; Erika Martinelli; Teresa Troiani; Fortunato Ciardiello; Patrizia Racca; Andrea Bertotti; Giulia Siravegna; Valter Torri; Alessio Amatu; Silvia Ghezzi; Giovanna Marrapese; Laura Palmeri; Emanuele Valtorta; Andrea Cassingena; Calogero Lauricella; Angelo Vanzulli; Daniele Regge; Silvio Veronese; Paolo M Comoglio; Alberto Bardelli; Silvia Marsoni; Salvatore Siena
Journal:  Lancet Oncol       Date:  2016-04-20       Impact factor: 41.316

3.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Authors:  Andrea Bertotti; Giorgia Migliardi; Francesco Galimi; Francesco Sassi; Davide Torti; Claudio Isella; Davide Corà; Federica Di Nicolantonio; Michela Buscarino; Consalvo Petti; Dario Ribero; Nadia Russolillo; Andrea Muratore; Paolo Massucco; Alberto Pisacane; Luca Molinaro; Emanuele Valtorta; Andrea Sartore-Bianchi; Mauro Risio; Lorenzo Capussotti; Marcello Gambacorta; Salvatore Siena; Enzo Medico; Anna Sapino; Silvia Marsoni; Paolo M Comoglio; Alberto Bardelli; Livio Trusolino
Journal:  Cancer Discov       Date:  2011-09-02       Impact factor: 39.397

4.  Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer.

Authors:  Giulia Siravegna; Luca Lazzari; Giovanni Crisafulli; Andrea Sartore-Bianchi; Benedetta Mussolin; Andrea Cassingena; Cosimo Martino; Richard B Lanman; Rebecca J Nagy; Stephen Fairclough; Giuseppe Rospo; Giorgio Corti; Alice Bartolini; Pamela Arcella; Monica Montone; Francesca Lodi; Annalisa Lorenzato; Alice Vanzati; Emanuele Valtorta; Giovanni Cappello; Andrea Bertotti; Sara Lonardi; Vittorina Zagonel; Francesco Leone; Mariangela Russo; Antonella Balsamo; Mauro Truini; Federica Di Nicolantonio; Alessio Amatu; Erica Bonazzina; Silvia Ghezzi; Daniele Regge; Angelo Vanzulli; Livio Trusolino; Salvatore Siena; Silvia Marsoni; Alberto Bardelli
Journal:  Cancer Cell       Date:  2018-07-09       Impact factor: 31.743

Review 5.  Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.

Authors:  S Siena; A Sartore-Bianchi; S Marsoni; H I Hurwitz; S J McCall; F Penault-Llorca; S Srock; A Bardelli; L Trusolino
Journal:  Ann Oncol       Date:  2018-05-01       Impact factor: 32.976
  5 in total
  5 in total

Review 1.  Precision oncology in metastatic colorectal cancer - from biology to medicine.

Authors:  Federica Di Nicolantonio; Pietro Paolo Vitiello; Silvia Marsoni; Salvatore Siena; Josep Tabernero; Livio Trusolino; Rene Bernards; Alberto Bardelli
Journal:  Nat Rev Clin Oncol       Date:  2021-04-16       Impact factor: 66.675

Review 2.  Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline.

Authors:  Irene S Yu; Francine Aubin; Rachel Goodwin; Jonathan M Loree; Cheryl Mather; Brandon S Sheffield; Stephanie Snow; Sharlene Gill
Journal:  Ther Adv Med Oncol       Date:  2022-07-20       Impact factor: 5.485

Review 3.  Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene.

Authors:  Javier Torres-Jiménez; Jorge Esteban-Villarrubia; Reyes Ferreiro-Monteagudo
Journal:  Cancers (Basel)       Date:  2022-07-30       Impact factor: 6.575

4.  Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.

Authors:  Andrea Sartore-Bianchi; Sara Lonardi; Cosimo Martino; Elisabetta Fenocchio; Federica Tosi; Silvia Ghezzi; Francesco Leone; Francesca Bergamo; Vittorina Zagonel; Fortunato Ciardiello; Andrea Ardizzoni; Alessio Amatu; Katia Bencardino; Emanuele Valtorta; Elena Grassi; Valter Torri; Emanuela Bonoldi; Anna Sapino; Angelo Vanzulli; Daniele Regge; Giovanni Cappello; Alberto Bardelli; Livio Trusolino; Silvia Marsoni; Salvatore Siena
Journal:  ESMO Open       Date:  2020-09

Review 5.  Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges.

Authors:  Erika Durinikova; Kristi Buzo; Sabrina Arena
Journal:  J Exp Clin Cancer Res       Date:  2021-06-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.